EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access

Comparative Effectiveness of Antihypertensive Medications in Children With Chronic Kidney Disease

Michelle R Denburg, Amy J Goodwin Davies, Mitchell G Maltenfort, Mark M Mitsnefes, Joseph T Flynn, Alicia M Neu, Bradley P Dixon, Dorey A Glenn, Caroline A Gluck, Lyndsay A Harshman, Chryso P Katsoufis, Mary B Leonard und 16 weitere

JAMA Pediatrics · 01.05.2026 · 180 (5) · 546

DOI: 10.1001/jamapediatrics.2026.0207 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA Pediatrics, erschienen am 01.05.2026. Verfasst von Michelle R Denburg und 27 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Antihypertensive Agents, Renal Insufficiency, Chronic, Hypertension, Calcium Channel Blockers. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Hypertension is a major modifiable factor for kidney function decline in chronic kidney disease (CKD). Comparative trials of antihypertensive medications in pediatric CKD are lacking.

Objective

To evaluate the comparative effectiveness of renin-angiotensin-aldosterone system inhibition (RAASi) vs calcium channel blockade (CCB), the most widely used first-line antihypertensive treatment approaches in pediatric CKD, on preservation of kidney function. Design, Setting, and Participants Using target trial emulation methods, this comparative-effectiveness study emulated a pragmatic, open-label clinical trial using electronic health record data from the Preserving Kidney Function in Children with CKD (PRESERVE) study from January 2009 through December 2020. Thirteen health care institutions from 5 PCORnet Clinical Research Networks were represented. Children and adolescents aged 2 to 20.9 years with CKD stage 2-4 and systolic blood pressure higher than the 90th percentile or with a hypertension diagnosis who initiated treatment with RAASi or CCB were included. Exclusion criteria included kidney replacement therapy, renal artery stenosis, malignancy, and pregnancy. Data analysis was completed in July 2025. Exposures Incident RAASi or CCB treatment. Randomization was emulated by propensity score weighting to balance groups on sociodemographic factors, institution, year, CKD etiology, proteinuria, CKD stage, obesity, health care use, medications, comorbidities, and blood pressure control (percentage of time at greater than the 90th percentile). Main Outcomes and Measures The primary outcome was progression to kidney replacement therapy within 2 years of follow-up, ascertained through linkage with the United States Renal Data System. The secondary outcome was a composite of kidney replacement therapy, 50% decline in estimated glomerular filtration rate, or estimated glomerular filtration rate less than 15 mL/min/1.73 m 2 . Cox proportional hazards regression with propensity score stratification was used to estimate adjusted hazard ratios (aHRs) in the intention-to-treat analysis. Adjusted analyses also compared systolic blood pressure control within 2 years of follow-up.

Results

Of 2762 children and adolescents, 1757 initiated RAASi (median [IQR] age, 13.1 [9.2-15.5] years; 897 [51.1%] male) and 1005 initiated CCB (median [IQR] age, 12.6 [8.4-15.3] years; 500 [49.8%] male). In adjusted analyses, RAASi was associated with reduced risk of both kidney replacement therapy (aHR, 0.58; 95% CI, 0.40-0.84, P = .004) and the secondary composite outcome (aHR, 0.67; 95% CI, 0.53-0.83). Systolic blood pressure control was better with RAASi than CCB (29% vs 39% of time >90th percentile). Conclusions and Relevance In this comparative-effectiveness study, RAASi was associated with lower risk of CKD progression and better blood pressure control compared to CCB. Findings support first-line use of RAASi for antihypertensive treatment in pediatric CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsRenal Insufficiency, ChronicHypertensionCalcium Channel BlockersAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHumansChildFemaleAdolescentMaleChild, PreschoolComparative Effectiveness ResearchYoung AdultTreatment Outcome

Substanzen

Antihypertensive AgentsCalcium Channel BlockersAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
  • Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Seattle Children's Hospital, University of Washington School of Medicine, Seattle.
  • Johns Hopkins Children's Center, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Children's Hospital Colorado, University of Colorado School of Medicine, Aurora.

Zitieren

APA

Denburg, M. R., Goodwin Davies, A. J., Maltenfort, M. G., Mitsnefes, M. M., Flynn, J. T., Neu, A. M., Dixon, B. P., Glenn, D. A., Gluck, C. A., Harshman, L. A., Katsoufis, C. P., Leonard, M. B., Modi, Z. J., Pan, C. G., Patel, H. P., Patterson, L. T., Verghese, P. S., Wilson, A. C., Jovanovska, A., …, & PRESERVE consortium (2026). Comparative Effectiveness of Antihypertensive Medications in Children With Chronic Kidney Disease. JAMA Pediatrics, 180(5), 546. https://doi.org/10.1001/jamapediatrics.2026.0207

Vancouver

Denburg MR, Goodwin Davies AJ, Maltenfort MG, Mitsnefes MM, Flynn JT, Neu AM, et al. Comparative Effectiveness of Antihypertensive Medications in Children With Chronic Kidney Disease. JAMA Pediatrics. 2026;180(5):546. doi:10.1001/jamapediatrics.2026.0207

BibTeX
@article{Denburg2026,
  author = {Denburg, Michelle R and Goodwin Davies, Amy J and Maltenfort, Mitchell G and Mitsnefes, Mark M and Flynn, Joseph T and Neu, Alicia M and Dixon, Bradley P and Glenn, Dorey A and Gluck, Caroline A and Harshman, Lyndsay A and Katsoufis, Chryso P and Leonard, Mary B and Modi, Zubin J and Pan, Cynthia G and Patel, Hiren P and Patterson, Larry T and Verghese, Priya S and Wilson, Amy C and Jovanovska, Aneta and Levondosky, Rebecca and Levondosky, Mark and Dickinson, Kimberley and Wieand, Kaleigh and Razzaghi, Hanieh and Li, Lu and Chen, Yong and Forrest, Christopher B and PRESERVE consortium, PRESERVE consortium},
  title = {Comparative Effectiveness of Antihypertensive Medications in Children With Chronic Kidney Disease},
  journal = {JAMA Pediatrics},
  year = {2026},
  volume = {180},
  number = {5},
  pages = {546},
  doi = {10.1001/jamapediatrics.2026.0207}
}
Kostenlos starten →